| Price | 51.50p on 30-01-2026 at 17:05:07 |
|---|---|
| Change | -1.50p -2.83% |
| Buy | 53.00p |
| Sell | 50.00p |
| Last Trade: | Buy 5,706.00 at 52.50p |
| Day's Volume: | 2,056,699 |
| Last Close: | 51.50p |
| Open: | 53.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 51.00p - 51.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £225.38m |
| VWAP: | 51.16919p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 5,706 | 52.50p | Ordinary |
16:28:45 - 30-Jan-26 |
| Buy* | 992 | 52.50p | Ordinary |
16:28:01 - 30-Jan-26 |
| Buy* | 45,000 | 51.90p | Ordinary |
16:25:48 - 30-Jan-26 |
| Buy* | 480 | 52.00p | Ordinary |
16:24:30 - 30-Jan-26 |
| Buy* | 500 | 51.3526p | Ordinary |
16:20:25 - 30-Jan-26 |
| Buy* | 7,188 | 51.90p | Ordinary |
16:20:14 - 30-Jan-26 |
| Buy* | 1,449 | 51.3526p | Ordinary |
16:19:27 - 30-Jan-26 |
| Buy* | 500 | 52.00p | SI Trade |
16:19:17 - 30-Jan-26 |
| Sell* | 50,000 | 51.35p | Ordinary |
16:18:57 - 30-Jan-26 |
| Sell* | 2,000 | 51.4126p | Ordinary |
16:16:53 - 30-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
